Search the Newsreel

Enterprise value to EBIT forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF

This article provides financial data for bioAffinity Technologies, Inc. (NASDAQ: BIAF), specifically its Enterprise Value to EBIT forward. The content is presented through TradingView, offering an overview of financials, news, and community sentiment for the company. The data is supplied by ICE Data Services …

BioAge Labs posts partial recovery after deep selloff, rises 19% (BIOA:NASDAQ)

BioAge Labs (BIOA) saw its shares rise by 19% on Monday, marking a partial recovery after a significant 64% plunge on Friday. The initial selloff was attributed to Novo Nordisk's trial failure, which impacted BioAge Labs due to market concerns about similar drug mechanisms. …

BTIG Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $40

BTIG has reiterated its Buy rating for BioAge Labs (BIOA.US) and maintained its target price at $40. This indicates a continued positive outlook from BTIG on the company's stock performance.

Janus Henderson Group PLC Acquires 1,685,063 Shares of BioAge Labs, Inc. $BIOA

BioAge Labs (NASDAQ:BIOA) Given Buy Rating at BTIG Research

bioAffinity Technologies Faces Nasdaq Delisting Risk After Notice

bioAffinity Technologies (BIAF) has received a delisting notice from Nasdaq because its stock failed to maintain the minimum $1.00 bid price for 30 consecutive business days. The company is ineligible for the standard compliance period due to a reverse stock split in the previous …

bioAffinity Technologies Received Notice of Delisting

bioAffinity Technologies (BIAF) has received a delisting notice from Nasdaq because its stock failed to maintain the minimum $1.00 bid price for 30 consecutive business days. The company is ineligible for the standard compliance period due to a reverse stock split in the previous …

Monte Rosa, BioAge plunge after Novo’s setback (GLUE:NASDAQ)

Shares of Monte Rosa Therapeutics (GLUE) and BioAge Labs (BIOA) experienced significant declines after Novo Nordisk's (NVO) late-stage trial setback cast doubt on the mechanisms underlying their experimental heart disease therapies. The failure of Novo Nordisk's drug, which targeted hsCRP, raised questions about whether …

Price to earnings forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF

This article provides financial information for bioAffinity Technologies, Inc. (NASDAQ: BIAF) on TradingView. It specifically highlights the company's "Price to earnings forward" metric. The content emphasizes that the data is compiled by humans and sourced from ICE Data Services and FactSet.

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs (NASDAQ: BIOA) stock significantly dropped after Novo Nordisk's ZEUS trial results for ziltivekimab, an experimental drug, failed to reduce major adverse cardiovascular events. This outcome has led William Blair analyst Andy Hsieh to question the link between hsCRP reduction and cardiovascular protection, …

BioAge Labs Down Over 61%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk

BioAge Labs, Inc. (BIOA) is experiencing a significant downturn, with its stock price at $9.61, representing a 61.33% decrease. This puts the company on track for its largest percentage decrease since December 2024 and its worst weekly and monthly performance since the same period. …

BIOAGE LABS INC : NEEDHAM CUTS TARGET PRICE TO $35 FROM $50

Needham has cut its target price for BIOAGE LABS INC (BIOA.O) shares to $35 from the previous $50. This information was reported by Reuters on July 31, 2026. The article advises readers that the content reflects only the author's opinion and is not investment …

BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update

BCAB Q2'26 Earnings: revenue estimate is 0 USD

BioAtla, Inc. (BCAB) is scheduled to release its Q2'26 earnings on August 6, 2026, at 8:00 AM ET (12:00 PM UTC). The company's revenue estimate for the quarter is $0 USD, with an anticipated EPS (earnings per share) of ($8.50) USD.

BIOAGE Labs Inc (BIOA) Institutional Confidence

The article details the institutional confidence score for BIOAGE Labs Inc (BIOA), which is currently 5.00, placing it 132nd in the Biotechnology & Medical Research industry. Institutional shareholding stands at 65.54%, marking a 24.58% decrease quarter-over-quarter. Key institutional shareholders and their share movements are …

BIOA|BIOAGE Labs Inc|Price:21.950|Chg%:+1.070

This article provides a comprehensive stock analysis of BIOAGE Labs Inc (BIOA) by TradingKey, highlighting its strong fundamentals, high growth potential, and "Buy" rating from analysts with a target price of $42.88. The company is in a growing phase, has high profit growth, and …

Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026

STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 29.3 billion …

BCAB|Bioatla Inc|Price:3.460|Chg%:+0.130

BIAF|bioAffinity Technologies Inc|Price:0.593|Chg%:-0.035

bioAffinity Technologies Inc. (BIAF) currently trades at $0.644, up 10.15% at market close on July 30th, 2026, with a market cap of $2.90M. The company, which specializes in noninvasive diagnostics for early-stage lung cancer, has shown strong revenue and profit growth but its stock …

Press Release issued by bioAffinity Technologies, Inc., dated July 27, 2026 - SEC.gov

bioAffinity Technologies announced the publication of a new clinical framework white paper, "Lung Nodules, Lung Microenvironment, Predictive Models and Clinician Risk Stratification Using CyPath ® Lung Testing for Early Diagnosis of Lung Cancer," authored by its Chief Medical Officer. This framework integrates CyPath ® …

bioAffinity Technologies, Inc. Revenue Breakdown – BOATS:BIAFW

bioAffinity Technologies, Inc. (BIAFW) generated $6.16 million USD in revenue last year, primarily from its Laboratory Services segment, which also contributed the most in the previous year at $9.35 million USD. The majority of this revenue, $6.16 million USD, originated from the United States, …

bioAffinity, Pictor Collaborate on Asthma and COPD Tests

bioAffinity Technologies and Pictor, Inc. have announced a collaboration to develop and commercialize diagnostic tests for asthma and COPD. These tests will combine flow cytometry and targeted proteomic analysis of sputum samples to identify specific inflammatory pathways, aiming to advance precision medicine for chronic …

bioAffinity Technologies publishes clinical framework to integrate CyPath® Lung into nodule evaluation

bioAffinity Technologies has published a clinical review outlining a practical framework to integrate CyPath® Lung into pulmonary nodule evaluation and cancer surveillance. The white paper, presented by CMO Dr. Gordon H. Downie, targets primary care, interventional pulmonology, and oncology practices to improve risk stratification. …

BioAge Labs, Inc. $BIOA Shares Sold by Orbimed Advisors LLC

Orbimed Advisors LLC reduced its stake in BioAge Labs (NASDAQ:BIOA) by 10% in the first quarter, selling 79,090 shares and retaining 711,811 shares valued at approximately $12.45 million. Despite this, other institutional investors like Geode Capital Management, Marshall Wace, and Mirae Asset Global ETFs …

Octagon Capital Advisors LP Has $30.57 Million Stock Position in BioAge Labs, Inc. $BIOA

Octagon Capital Advisors LP has increased its holdings in BioAge Labs, Inc. by 9.4%, now owning 1.748 million shares valued at $30.57 million. BioAge Labs, a clinical-stage biotechnology company, reported a smaller-than-expected quarterly loss of $0.52 per share on $2.77 million in revenue, though …

Bioatla Inc (BCAB) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Bioatla Inc (BCAB), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for top firms. The data focuses on …

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

bioAffinity Technologies has published a new clinical framework in a white paper titled "Lung Nodules, Lung Microenvironment, Predictive Models and Clinician Risk Stratification Using CyPath® Lung Testing for Early Diagnosis of Lung Cancer." This framework outlines how CyPath® Lung, a noninvasive test, can be …

BIOAGE Labs Inc (BIOA) Income Statement - Tradingkey.com

This article provides the income statement for BIOAGE Labs Inc (BIOA), detailing both quarterly and annual financial performance. It includes key metrics such as total revenue, operating expenses, net income, and earnings per share, along with year-over-year comparisons. The page also offers a FAQ …

Bioatla Inc (BCAB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Bioatla Inc (BCAB), detailing its current valuation score and P/E ratio. It notes that the company ranks highly within the Biotechnology & Medical Research industry for its valuation. However, key valuation metrics like P/B, P/S, and P/CF …

Bioatla Inc (BCAB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Bioatla Inc (BCAB). It notes that no dividends have been distributed in the past 5 years and details a future merger stock split event scheduled for March 31, 2026, with a 50:1 ratio. The …

BioAtla, Inc. Revenue Breakdown – NASDAQ:BCAB

BioAtla, Inc. (NASDAQ: BCAB) revenue breakdown shows that the United States was the greatest contributor to its revenue. Last year, the U.S. accounted for $2.00 million USD, a decrease from $11.00 million USD the previous year. This data highlights the company's regional financial performance.

Bioatla Inc (BCAB) Cash Flow

This article provides a detailed cash flow statement for Bioatla Inc (BCAB), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, changes in working capital, capital expenditures, and debt issuance/repayment. The content also includes …

BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

This article compares two cancer diagnostics companies, bioAffinity Technologies (BIAF) and Biodesix (BDSX), to determine which is a better investment. While BIAF focuses on early-stage lung cancer detection with its CyPath Lung test and has strong growth potential, it is in an earlier commercial …

BioAge Labs, Inc. Revenue Breakdown – NASDAQ:BIOA

This article provides details on BioAge Labs, Inc. (NASDAQ: BIOA), primarily focusing on its financial data and market information available through TradingView. It highlights where to find financials, statistics, dividends, earnings, and segment performance. The content is essentially a snapshot of a financial data …

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD | Newswise

bioAffinity Technologies and Pictor®, Inc. have partnered to develop and commercialize bioAffinity's next-generation diagnostic tests for asthma and chronic obstructive pulmonary disease (COPD). This collaboration aims to enhance the throughput and reduce the costs of personalized testing by integrating bioAffinity's flow cytometry expertise with …

bioAffinity Technologies Inc (BIAF) Cash Flow Statement

This article presents the quarterly and annual cash flow statements for bioAffinity Technologies Inc (BIAF), detailing operating, investing, and financing cash flows. It includes financial figures for various quarters and years, along with definitions and FAQs about different types of cash flow and their …